Swiss Economy Rebounds In Q1

By Renju Jay  ✉   | Published:

The Swiss rebounded at a faster-than-expected pace at the start of the year on robust domestic demand, government data showed on Tuesday.

Gross domestic product grew 0.3 percent sequentially in the first quarter after stagnating in the fourth quarter of 2022, the State Secretariat for Economic Affairs, or SECO, reported. The rate also exceeded economists' forecast of 0.1 percent expansion.

GDP, adjusted for sports events, logged a quarterly growth of 0.5 percent after posting a nil growth.

The expenditure-side of GDP showed that private consumption, investment and exports were the major drivers of growth.

Private spending registered a faster increase of 0.6 percent following a 0.2 percent rise a quarter ago. There was significant increase in consumer spending on services, such as mobility and tourism.

At the same time, government consumption remained flat after a 0.1 percent drop.

The quarterly growth in equipment and software investment improved to 2.6 percent from 0.1 percent, driven by higher investment in research and development. Meanwhile, construction investment was down 0.1 percent.

Exports of goods surged 4.0 percent, while shipment of services decreased 5.5 percent. At the same time, imports of goods moved up 5.4 percent and that of services gained 1.4 percent.

Overall, the contribution of foreign trade to GDP growth was slightly negative, data showed.

On a yearly basis, economic growth slowed marginally to 0.6 percent from 0.7 percent. The rate came in line with expectations.

Despite the rebound, the Swiss economy is set to slow over the remainder of the year as the effects of monetary tightening intensify, Capital Economics' economist Adrian Prettejohn said.

In March, the Swiss National Bank had projected the economy to grow around 1 percent this year.

The outlook for the economy continued to darken, a survey data from the Zurich-based KOF Swiss Economic Institute showed Tuesday. The KOF Economic Barometer fell to 90.2 in May from revised 96.4 in April. The indicator declined for the second straight month.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Elon Musk's brain implant firm Neuralink said it has received approval from the U.S. Food and Drug Administration to conduct first-in-human clinical trials. In a tweet, Neuralink said, "We are excited to share that we have received the FDA's approval to launch our first-in-human clinical study! T.W. Garner Food Co. is recalling 50,688 bottles of 12 oz. Texas Pete Buffalo Wing Sauce citing undeclared soy, the U.S. Food and Drug Administration said. The agency noted that some of the bottles may contain Texas Pete Extra Mild Wing Sauce which contains soy. The recall involves Texas Pete Buffalo Wing Sauce with best used by 120623T 065239 UPC 0 75500 10011 6. The U.S. Food and Drug Administration approved Pfizer Inc's COVID-19 oral antiviral pill Paxlovid for the treatment of mild-to-moderate COVID-19 in adults. Paxlovid is the first oral treatment, and the fourth drug, approved by the agency to treat COVID-19 in adults. Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) has been approved to treat adults who are at high...